Low-dose apixiban comparable to full dose for preventing VTE recurrence in patients with cancer 2.5 mg twice-daily dose as effective and safer than full dose in API-CAT trial Peer-Reviewed Publication ...

At 12 months, 18 patients in the reduced-dose group and 24 in the full-dose group had had a recurrent VTE (12-months cumulative incidence of 2.1% and 2.8% respectively), a difference that was ...

The low-dose direct oral anticoagulant (DOAC) performed better in the 3-month primary endpoint counting thromboembolic events and device-related thrombosis (4.6% vs 21.7% with DAPT, HR 0.18, 95% ...

The ATLAS-ACS trial demonstrated that very low-dose rivaroxaban reduced MI and cardiovascular death, ... 2011). In contrast to APPRAISE-2, which used "therapeutic-dose" apixaban (i.e., ...

Extended Reduced-Dose Apixaban for Cancer-Associated VTE. 2025-04-10. DOI: 10.1056/NEJMdo007972. Save. Permissions. For permission requests, please contact NEJM Reprints at [email protected] ...